H.C. Wainwright initiated coverage of Acrivon Therapeutics with a Buy rating and $24 price target. The company utilizes its proteomics based patient selection platform, Predictive Precision Proteomics, to create drug-tailored, automated, quantitative proteomic tissue imaging tests, the analyst tells investors in a research note. The firm says the platform could be broadly applied to drugs to improve probability of response.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ACRV:
- Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
- Acrivon Therapeutics expects cash to fund operations into 4Q24
- Acrivon Therapeutics reports Q4 EPS (80c) vs. ($2.45) last year
- Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
